Research programme: histone deacetylase-6 protein inhibitors - Karus Therapeutics

Drug Profile

Research programme: histone deacetylase-6 protein inhibitors - Karus Therapeutics

Alternative Names: HDAC-6 inhibitors - Karus; HDAC6i - Karus; KA 2507; KAR 2581; KAR 3000; KAR 3166

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; Kings College London; Queen Elizabeth Hospital
  • Class Antineoplastics; Depsipeptides; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Malignant melanoma; Solid tumours
  • Research Inflammation; Psoriasis; Rheumatoid arthritis
  • No development reported Transplant rejection

Most Recent Events

  • 30 Dec 2016 Karus Therapeutics plans a phase I trial for Solid tumours (Second-line therapy or greater) in USA (PO) (NCT03008018)
  • 21 Dec 2016 Preclinical trials in Malignant melanoma in United Kingdom (PO) before December 2016
  • 16 Apr 2016 Karus Therapeutics plans a phase I trial for Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top